ShockWave Medical (NASDAQ:SWAV) and Lyra Therapeutics (NASDAQ:LYRA) are both medical companies, but which is the superior stock? We will compare the two businesses based on the strength of their institutional ownership, analyst recommendations, dividends, profitability, earnings, valuation and risk.
Earnings and Valuation
This table compares ShockWave Medical and Lyra Therapeutics’ gross revenue, earnings per share and valuation.
|Gross Revenue||Price/Sales Ratio||Net Income||Earnings Per Share||Price/Earnings Ratio|
|ShockWave Medical||$42.93 million||107.12||-$51.11 million||($2.14)||-61.67|
Lyra Therapeutics has lower revenue, but higher earnings than ShockWave Medical.
Insider & Institutional Ownership
88.8% of ShockWave Medical shares are held by institutional investors. Comparatively, 59.3% of Lyra Therapeutics shares are held by institutional investors. 15.3% of ShockWave Medical shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth.
This is a summary of recent recommendations for ShockWave Medical and Lyra Therapeutics, as provided by MarketBeat.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
ShockWave Medical currently has a consensus price target of $112.50, suggesting a potential downside of 14.76%. Lyra Therapeutics has a consensus price target of $26.00, suggesting a potential upside of 124.91%. Given Lyra Therapeutics’ stronger consensus rating and higher probable upside, analysts clearly believe Lyra Therapeutics is more favorable than ShockWave Medical.
This table compares ShockWave Medical and Lyra Therapeutics’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Lyra Therapeutics beats ShockWave Medical on 6 of the 9 factors compared between the two stocks.
ShockWave Medical Company Profile
ShockWave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy technology to treat calcified plaque in patients with peripheral vascular, coronary vascular, and heart valve diseases. The company offers M5 catheters for treating above-the-knee peripheral artery disease; C2 catheters for treating coronary artery disease; and S4 catheters for treating below-the-knee peripheral artery disease. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and sales managers, and distributors. The company operates in the United States, Germany, rest of Europe, and internationally. ShockWave Medical, Inc. was incorporated in 2009 and is headquartered in Santa Clara, California.
Lyra Therapeutics Company Profile
Lyra Therapeutics, Inc., a clinical-stage therapeutics company, focuses on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The company's XTreo technology platform is designed to deliver medicines directly to the affected tissue for sustained periods with a single administration. Its product candidates include LYR-210, an anti-inflammatory implantable drug matrix for the treatment of chronic rhinosinusitis (CRS), which is in Phase II clinical trial; and LYR-220 for CRS patients with and without nasal polyps. The company was formerly known as 480 Biomedical, Inc. and changed its name to Lyra Therapeutics, Inc. in July 2018. Lyra Therapeutics, Inc. was incorporated in 2005 and is headquartered in Watertown, Massachusetts.